pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Xcopri
drug · small molecule
save

cenobamate

Marketedupdated 3mo ago
by SK Life Science Inc🔗 ChEMBL
Approved
community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 3 investigational indications.

targets

Sodium channel alpha subunitGABA-A receptor; anion channel

all catalysts(0)

nothing on the calendar yet

Trials studying cenobamate

  • phase4Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsyactive not recruitingn=49
  • phase3A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Oldsrecruitingn=20
  • phase3Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizuresactive not recruitingn=140
  • phase1Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizurescompletedn=26
  • phase3Cenobamate Open-Label Extension Study for YKP3089C025enrolling by invitationn=145
  • —Real-world Clinical Response to Cenobamate Early add-on in France, Germany and Spainrecruitingn=300
  • phase3Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizurescompletedn=169
  • phase3ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.recruitingn=15
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Oct 30, 2032
~6.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (12)

  • Jun 16, 2039method-of-use (U-3610)US 11654133
  • Jun 16, 2039method-of-use (U-3610)US 11654133
  • Jun 16, 2039method-of-use (U-3610)US 11654133
  • Jun 16, 2039method-of-use (U-3610)US 11654133
  • Jun 16, 2039method-of-use (U-3610)US 11654133
  • Jun 16, 2039method-of-use (U-3610)US 11654133
  • Oct 30, 2032compositionUS 7598279
  • Oct 30, 2032compositionUS 7598279
  • Oct 30, 2032compositionUS 7598279
  • Oct 30, 2032compositionUS 7598279
  • Oct 30, 2032compositionUS 7598279
  • Oct 30, 2032compositionUS 7598279

News(0)

no news has mentioned this drug yet

brand
Xcopri
trade names
Ontozry, Xcopri
generic
cenobamate
MOA
Sodium channel alpha subunit inhibitor; GABA-A receptor; anion channel positive allosteric modulator
indication
Tonic-Clonic (Grand Mal) Seizure
phase
marketed
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 2m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?